Cargando…

Teneligliptin in management of type 2 diabetes mellitus

Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. Teneligliptin has been recently available in Japan (Teneria(®)), Argentina (Teneglucon(®)), and India (Tenepure; Teneza)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Surendra Kumar, Panneerselvam, A, Singh, KP, Parmar, Girish, Gadge, Pradeep, Swami, Onkar C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993264/ https://www.ncbi.nlm.nih.gov/pubmed/27574456 http://dx.doi.org/10.2147/DMSO.S106133

Ejemplares similares

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh, Sujoy, et al.
Publicado: (2016)

Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications
por: Gadge, Pradeep, et al.
Publicado: (2018)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study
por: Agarwal, Piyush, et al.
Publicado: (2018)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Xiaoxuan, et al.
Publicado: (2018)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
por: Fushimi, Yoshiro, et al.
Publicado: (2020)

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)
por: Ghosh, Sujoy, et al.
Publicado: (2020)

Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
por: Kutoh, Eiji, et al.
Publicado: (2014)

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
por: Haneda, Masakazu, et al.
Publicado: (2018)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
por: Tandon, Tanya, et al.
Publicado: (2019)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
por: Seo, Da Hea, et al.
Publicado: (2021)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
por: Okuda, Yoshinori, et al.
Publicado: (2016)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
por: Erande, S, et al.
Publicado: (2019)

Teneligliptin and “Thorough QTc study”: thorough enough?
por: Ghosal, Samit
Publicado: (2019)

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis
por: Mitra, Asis, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
por: Kumar, Amit, et al.
Publicado: (2019)

Teneligliptin-induced hair loss: A case report
por: Agrawal, Prabhat K., et al.
Publicado: (2020)

Exanthematous Drug Eruption as a Side Effect of Teneligliptin
por: Sunil, Krupa A., et al.
Publicado: (2021)

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

An update on diagnosis and therapeutics for type-2 diabetes mellitus
por: Shyamaladevi, Babu, et al.
Publicado: (2023)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Ji, Linong, et al.
Publicado: (2020)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
por: Ji, Linong, et al.
Publicado: (2021)

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study
por: Sagara, Masaaki, et al.
Publicado: (2016)

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
por: Ito, Rika, et al.
Publicado: (2015)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
por: Ceriello, Antonio, et al.
Publicado: (2019)

Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022)

A clinical study on the Naimittika Rasayana effect of Silajatu and Mamajjaka in type-2 Diabetes Mellitus
por: Kumar, Sanjai, et al.
Publicado: (2014)

Clinical Prediction of Type 2 Diabetes Mellitus (T2DM) via Anthropometric and Biochemical Variations in Prakriti
por: Singh, Shriti, et al.
Publicado: (2022)

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Iron Profile and Glycaemic Control in Patients with Type 2 Diabetes Mellitus
por: Misra, Gunjan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dctufu55hrjuiujgvj2esgunao